Department of Internal Medicine, Riverside Shore Memorial Hospital, Onancock, Virginia, USA.
Department of Cardiology, Ain Shams University, Cairo, Egypt.
Catheter Cardiovasc Interv. 2024 Nov;104(5):928-933. doi: 10.1002/ccd.31198. Epub 2024 Aug 27.
Chronic systemic anticoagulation use is prevalent for various thromboembolic conditions. Anticoagulation (usually through heparin products) is also recommended for the initial management of non-ST-elevation myocardial infarction (NSTEMI).
To evaluate the in-hospital outcomes of patients with NSTEMI who have been on chronic anticoagulation.
Using the National Inpatient Sample (NIS) years 2016-2020, NSTEMI patients and patients with chronic anticoagulation were identified using the appropriate International Classification of Diseases, 10th version (ICD-10) appropriate codes. The primary outcome was all-cause in-hospital mortality while the secondary outcomes included major bleeding, ischemic cerebrovascular accident (CVA), early percutaneous coronary intervention (PCI) (i.e., within 24 h of admission), coronary artery bypass graft (CABG) during hospitalization, length of stay (LOS), and total charges. Multivariate logistic or linear regression analyses were performed after adjusting for patient-level and hospital-level factors.
Among 2,251,914 adult patients with NSTEMI, 190,540 (8.5%) were on chronic anticoagulation. Chronic anticoagulation use was associated with a lower incidence of in-hospital mortality (adjusted odds ratio [aOR]: 0.69, 95% confidence interval [CI]: 0.65-0.73, p < 0.001). There was no significant difference in major bleeding (aOR: 0.95, 95% CI: 0.88-1.0, p = 0.15) or ischemic CVA (aOR: 0.23, 95% CI: 0.03-1.69, p = 0.15). Chronic anticoagulation use was associated with a lower incidence of early PCI (aOR: 0.78, 95% CI: 0.76-0.80, p < 0.001) and CABG (aOR: 0.43, 95% CI: 0.41-0.45, p < 0.001). Chronic anticoagulation was also associated with decreased LOS and total charges (adjusted mean difference [aMD]: -0.8 days, 95% CI: -0.86 to -0.75, p < 0.001) and (aMD: $-19,340, 95% CI: -20,692 to -17,988, p < 0.001).
Among patients admitted with NSTEMI, chronic anticoagulation use was associated with lower in-hospital mortality, LOS, and total charges, with no difference in the incidence of major bleeding.
慢性全身性抗凝治疗在各种血栓栓塞性疾病中很常见。对于非 ST 段抬高型心肌梗死(NSTEMI),也推荐使用抗凝治疗(通常通过肝素类产品)进行初始治疗。
评估正在接受慢性抗凝治疗的 NSTEMI 患者的住院期间结局。
使用国家住院患者样本(NIS)2016-2020 年的数据,使用适当的国际疾病分类,第 10 版(ICD-10)适当的代码,确定 NSTEMI 患者和慢性抗凝治疗患者。主要结局是全因住院期间死亡率,次要结局包括主要出血、缺血性脑血管意外(CVA)、早期经皮冠状动脉介入治疗(PCI)(即入院后 24 小时内)、住院期间冠状动脉旁路移植术(CABG)、住院时间(LOS)和总费用。在调整了患者水平和医院水平的因素后,进行了多变量逻辑或线性回归分析。
在 2251914 名成年 NSTEMI 患者中,有 190540 名(8.5%)正在接受慢性抗凝治疗。慢性抗凝治疗与较低的住院期间死亡率相关(调整后的优势比[aOR]:0.69,95%置信区间[CI]:0.65-0.73,p<0.001)。主要出血(aOR:0.95,95%CI:0.88-1.0,p=0.15)或缺血性 CVA(aOR:0.23,95%CI:0.03-1.69,p=0.15)发生率无显著差异。慢性抗凝治疗与较低的早期 PCI(aOR:0.78,95%CI:0.76-0.80,p<0.001)和 CABG(aOR:0.43,95%CI:0.41-0.45,p<0.001)发生率相关。慢性抗凝治疗还与 LOS 和总费用的减少相关(调整后的平均差值[aMD]:-0.8 天,95%CI:-0.86 至-0.75,p<0.001)和(aMD:-19340 美元,95%CI:-20692 美元至-17988 美元,p<0.001)。
在因 NSTEMI 住院的患者中,慢性抗凝治疗与较低的住院期间死亡率、LOS 和总费用相关,主要出血发生率无差异。